Interface-Engineered Mesoporous FeB with Programmed Drug Release for Synergistic Cancer Theranostics.
Sign Up to like & getrecommendations! Published in 2022 at "ACS applied materials & interfaces"
DOI: 10.1021/acsami.2c09419
Abstract: The pursuit of mesoporous Fe-based nanoagents addresses the field of developing alternative Fe-bearing nanoagents for synergistic cancer therapy with the expectation that the use of an essential element may avoid the issues raised by the… read more here.
Keywords: dox; synergistic cancer; mfeb; release ... See more keywords